{"frames":[{"target":{"name":"Frequency","spans":[{"start":0,"end":1,"text":"Annual"}]},"annotationSets":[{"rank":0,"score":32.44726627751411,"frameElements":[{"name":"Event","spans":[{"start":1,"end":2,"text":"review"}]},{"name":"Interval","spans":[{"start":0,"end":1,"text":"Annual"}]}]}]},{"target":{"name":"Medical_specialties","spans":[{"start":3,"end":4,"text":"medicine"}]},"annotationSets":[{"rank":0,"score":5.190858220391284,"frameElements":[{"name":"Specialty","spans":[{"start":3,"end":4,"text":"medicine"}]}]}]}],"tokens":["Annual","review","of","medicine",",","vol","66","."]}
{"frames":[{"target":{"name":"Trial","spans":[{"start":9,"end":10,"text":"Trial"}]},"annotationSets":[{"rank":0,"score":39.606909538784336,"frameElements":[{"name":"Defendant","spans":[{"start":8,"end":9,"text":"Vaccine"}]}]}]},{"target":{"name":"Scrutiny","spans":[{"start":12,"end":13,"text":"Search"}]},"annotationSets":[{"rank":0,"score":44.28355459479458,"frameElements":[{"name":"Ground","spans":[{"start":13,"end":17,"text":"for Correlates of Protection"}]}]}]},{"target":{"name":"Protecting","spans":[{"start":16,"end":17,"text":"Protection"}]},"annotationSets":[{"rank":0,"score":64.3903561283932,"frameElements":[{"name":"Protection","spans":[{"start":16,"end":17,"text":"Protection"}]}]}]}],"tokens":["Lessons","from","the","RV144","Thai","Phase","III","HIV-1","Vaccine","Trial","and","the","Search","for","Correlates","of","Protection","."]}
{"frames":[{"target":{"name":"State_continue","spans":[{"start":1,"end":2,"text":"remains"}]},"annotationSets":[{"rank":0,"score":25.90070609948917,"frameElements":[{"name":"State","spans":[{"start":5,"end":6,"text":"vaccine"}]},{"name":"Entity","spans":[{"start":0,"end":1,"text":"RV144"}]}]}]},{"target":{"name":"Sole_instance","spans":[{"start":3,"end":4,"text":"only"}]},"annotationSets":[{"rank":0,"score":2.77944737185381,"frameElements":[]}]},{"target":{"name":"Trial","spans":[{"start":6,"end":7,"text":"trial"}]},"annotationSets":[{"rank":0,"score":42.01924022407775,"frameElements":[{"name":"Defendant","spans":[{"start":5,"end":6,"text":"vaccine"}]}]}]},{"target":{"name":"Reasoning","spans":[{"start":8,"end":9,"text":"demonstrate"}]},"annotationSets":[{"rank":0,"score":40.39564151058086,"frameElements":[{"name":"Content","spans":[{"start":9,"end":13,"text":"efficacy against HIV-1 acquisition"}]},{"name":"Arguer","spans":[{"start":5,"end":6,"text":"vaccine"}]}]}]},{"target":{"name":"Getting","spans":[{"start":12,"end":13,"text":"acquisition"}]},"annotationSets":[{"rank":0,"score":51.297492713267204,"frameElements":[]}]}],"tokens":["RV144","remains","the","only","HIV-1","vaccine","trial","to","demonstrate","efficacy","against","HIV-1","acquisition","."]}
{"frames":[{"target":{"name":"Scrutiny","spans":[{"start":2,"end":3,"text":"analysis"}]},"annotationSets":[{"rank":0,"score":47.84915015006186,"frameElements":[]}]},{"target":{"name":"Run_risk","spans":[{"start":7,"end":8,"text":"risk"}]},"annotationSets":[{"rank":0,"score":52.77219317348792,"frameElements":[]}]},{"target":{"name":"Evidence","spans":[{"start":8,"end":9,"text":"showed"}]},"annotationSets":[{"rank":0,"score":37.922429049485785,"frameElements":[{"name":"Proposition","spans":[{"start":9,"end":57,"text":"that antibodies directed against the V1V2 region of gp120 , in particular the IgG1 and IgG3 subclass mediating antibody-dependent cell-mediated cytotoxicity , seem to play a predominant role in protection against HIV-1 acquisition and that plasma envelope -LRB- Env -RRB- -specific IgA antibodies were directly correlated with risk"}]},{"name":"Support","spans":[{"start":0,"end":8,"text":"The prespecified analysis of immune correlates of risk"}]}]}]},{"target":{"name":"Behind_the_scenes","spans":[{"start":11,"end":12,"text":"directed"}]},"annotationSets":[{"rank":0,"score":37.41761127001372,"frameElements":[]}]},{"target":{"name":"Locale","spans":[{"start":15,"end":16,"text":"region"}]},"annotationSets":[{"rank":0,"score":36.015035052835984,"frameElements":[{"name":"Locale","spans":[{"start":15,"end":16,"text":"region"}]}]}]},{"target":{"name":"Appearance","spans":[{"start":31,"end":32,"text":"seem"}]},"annotationSets":[{"rank":0,"score":52.21618963220188,"frameElements":[{"name":"Phenomenon","spans":[{"start":24,"end":30,"text":"IgG3 subclass mediating antibody-dependent cell-mediated cytotoxicity"}]}]}]},{"target":{"name":"Performers_and_roles","spans":[{"start":33,"end":34,"text":"play"}]},"annotationSets":[{"rank":0,"score":39.247108299733995,"frameElements":[]}]},{"target":{"name":"Performers_and_roles","spans":[{"start":36,"end":37,"text":"role"}]},"annotationSets":[{"rank":0,"score":41.249374168041335,"frameElements":[]}]},{"target":{"name":"Protecting","spans":[{"start":38,"end":39,"text":"protection"}]},"annotationSets":[{"rank":0,"score":64.10529620508369,"frameElements":[{"name":"Protection","spans":[{"start":38,"end":39,"text":"protection"}]}]}]},{"target":{"name":"Getting","spans":[{"start":41,"end":42,"text":"acquisition"}]},"annotationSets":[{"rank":0,"score":52.23886432061889,"frameElements":[{"name":"Theme","spans":[{"start":40,"end":41,"text":"HIV-1"}]}]}]},{"target":{"name":"Containers","spans":[{"start":45,"end":46,"text":"envelope"}]},"annotationSets":[{"rank":0,"score":36.71944201182978,"frameElements":[{"name":"Container","spans":[{"start":45,"end":46,"text":"envelope"}]}]}]},{"target":{"name":"Run_risk","spans":[{"start":56,"end":57,"text":"risk"}]},"annotationSets":[{"rank":0,"score":52.77219317348792,"frameElements":[]}]}],"tokens":["The","prespecified","analysis","of","immune","correlates","of","risk","showed","that","antibodies","directed","against","the","V1V2","region","of","gp120",",","in","particular","the","IgG1","and","IgG3","subclass","mediating","antibody-dependent","cell-mediated","cytotoxicity",",","seem","to","play","a","predominant","role","in","protection","against","HIV-1","acquisition","and","that","plasma","envelope","-LRB-","Env","-RRB-","-specific","IgA","antibodies","were","directly","correlated","with","risk","."]}
{"frames":[{"target":{"name":"Relative_time","spans":[{"start":2,"end":3,"text":"recent"}]},"annotationSets":[{"rank":0,"score":19.295933932585516,"frameElements":[]}]},{"target":{"name":"Difficulty","spans":[{"start":5,"end":6,"text":"challenge"}]},"annotationSets":[{"rank":0,"score":29.37797346402879,"frameElements":[{"name":"Activity","spans":[{"start":17,"end":26,"text":"to induce protective antibody responses against mucosal HIV-1 acquisition"}]}]}]},{"target":{"name":"Education_teaching","spans":[{"start":6,"end":7,"text":"studies"}]},"annotationSets":[{"rank":0,"score":102.27082499947247,"frameElements":[]}]},{"target":{"name":"Statement","spans":[{"start":7,"end":8,"text":"suggest"}]},"annotationSets":[{"rank":0,"score":123.59030015269084,"frameElements":[{"name":"Message","spans":[{"start":8,"end":26,"text":"that Env is essential , and perhaps sufficient , to induce protective antibody responses against mucosal HIV-1 acquisition"}]}]}]},{"target":{"name":"Being_necessary","spans":[{"start":11,"end":12,"text":"essential"}]},"annotationSets":[{"rank":0,"score":49.457831671886176,"frameElements":[{"name":"Dependent","spans":[{"start":17,"end":26,"text":"to induce protective antibody responses against mucosal HIV-1 acquisition"}]}]}]},{"target":{"name":"Sufficiency","spans":[{"start":15,"end":16,"text":"sufficient"}]},"annotationSets":[{"rank":0,"score":12.282183948584048,"frameElements":[{"name":"Enabled_situation","spans":[{"start":17,"end":26,"text":"to induce protective antibody responses against mucosal HIV-1 acquisition"}]}]}]},{"target":{"name":"Causation","spans":[{"start":18,"end":19,"text":"induce"}]},"annotationSets":[{"rank":0,"score":61.3023239832621,"frameElements":[{"name":"Effect","spans":[{"start":19,"end":26,"text":"protective antibody responses against mucosal HIV-1 acquisition"}]}]}]},{"target":{"name":"Response","spans":[{"start":21,"end":22,"text":"responses"}]},"annotationSets":[{"rank":0,"score":44.07117466250505,"frameElements":[]}]},{"target":{"name":"Getting","spans":[{"start":25,"end":26,"text":"acquisition"}]},"annotationSets":[{"rank":0,"score":51.3099219652827,"frameElements":[{"name":"Theme","spans":[{"start":24,"end":25,"text":"HIV-1"}]}]}]}],"tokens":["RV144","and","recent","nonhuman","primate","challenge","studies","suggest","that","Env","is","essential",",","and","perhaps","sufficient",",","to","induce","protective","antibody","responses","against","mucosal","HIV-1","acquisition","."]}
{"frames":[{"target":{"name":"Trial","spans":[{"start":2,"end":3,"text":"trials"}]},"annotationSets":[{"rank":0,"score":48.137936846451055,"frameElements":[]}]},{"target":{"name":"Process_continue","spans":[{"start":4,"end":5,"text":"ongoing"}]},"annotationSets":[{"rank":0,"score":44.59335599396074,"frameElements":[{"name":"Event","spans":[{"start":0,"end":3,"text":"Follow-up clinical trials"}]}]}]},{"target":{"name":"Increment","spans":[{"start":6,"end":7,"text":"further"}]},"annotationSets":[{"rank":0,"score":15.52883362243319,"frameElements":[]}]},{"target":{"name":"Scrutiny","spans":[{"start":7,"end":8,"text":"dissect"}]},"annotationSets":[{"rank":0,"score":41.72614736030989,"frameElements":[{"name":"Ground","spans":[{"start":8,"end":11,"text":"the immune responses"}]}]}]},{"target":{"name":"Response","spans":[{"start":10,"end":11,"text":"responses"}]},"annotationSets":[{"rank":0,"score":38.58257193981197,"frameElements":[]}]},{"target":{"name":"Cause_to_start","spans":[{"start":11,"end":12,"text":"elicited"}]},"annotationSets":[{"rank":0,"score":30.28174941975623,"frameElements":[{"name":"Effect","spans":[{"start":12,"end":23,"text":"by the RV144 ALVAC-HIV and AIDSVAXR -LRB- R -RRB- B/E regimen"}]}]}]}],"tokens":["Follow-up","clinical","trials","are","ongoing","to","further","dissect","the","immune","responses","elicited","by","the","RV144","ALVAC-HIV","and","AIDSVAXR","-LRB-","R","-RRB-","B/E","regimen","."]}
{"frames":[{"target":{"name":"Scrutiny","spans":[{"start":1,"end":2,"text":"study"}]},"annotationSets":[{"rank":0,"score":51.89569085287765,"frameElements":[{"name":"Ground","spans":[{"start":2,"end":11,"text":"of gp120 Env immunogens and immune correlates of risk"}]}]}]},{"target":{"name":"Run_risk","spans":[{"start":10,"end":11,"text":"risk"}]},"annotationSets":[{"rank":0,"score":52.77219317348792,"frameElements":[]}]},{"target":{"name":"Causation","spans":[{"start":12,"end":13,"text":"resulted"}]},"annotationSets":[{"rank":0,"score":74.79370239824566,"frameElements":[{"name":"Cause","spans":[{"start":0,"end":11,"text":"The study of gp120 Env immunogens and immune correlates of risk"}]},{"name":"Effect","spans":[{"start":13,"end":19,"text":"in the development of improved antigens"}]}]}]},{"target":{"name":"Event","spans":[{"start":15,"end":16,"text":"development"}]},"annotationSets":[{"rank":0,"score":35.560205791353624,"frameElements":[{"name":"Event","spans":[{"start":16,"end":19,"text":"of improved antigens"}]}]}]},{"target":{"name":"Cause_to_make_progress","spans":[{"start":17,"end":18,"text":"improved"}]},"annotationSets":[{"rank":0,"score":71.87730332549827,"frameElements":[{"name":"Project","spans":[{"start":18,"end":19,"text":"antigens"}]}]}]}],"tokens":["The","study","of","gp120","Env","immunogens","and","immune","correlates","of","risk","has","resulted","in","the","development","of","improved","antigens","."]}
{"frames":[{"target":{"name":"Run_risk","spans":[{"start":6,"end":7,"text":"risk"}]},"annotationSets":[{"rank":0,"score":52.77219317348792,"frameElements":[]}]},{"target":{"name":"Increment","spans":[{"start":10,"end":11,"text":"other"}]},"annotationSets":[{"rank":0,"score":19.708474494763053,"frameElements":[{"name":"Class","spans":[{"start":11,"end":12,"text":"populations"}]}]}]},{"target":{"name":"Aggregate","spans":[{"start":11,"end":12,"text":"populations"}]},"annotationSets":[{"rank":0,"score":33.51401278612046,"frameElements":[{"name":"Aggregate","spans":[{"start":11,"end":12,"text":"populations"}]}]}]},{"target":{"name":"Similarity","spans":[{"start":14,"end":15,"text":"similar"}]},"annotationSets":[{"rank":0,"score":56.780939932970284,"frameElements":[{"name":"Entity_1","spans":[{"start":15,"end":16,"text":"immunogens"}]}]}]},{"target":{"name":"Similarity","spans":[{"start":17,"end":18,"text":"different"}]},"annotationSets":[{"rank":0,"score":46.0283119298151,"frameElements":[{"name":"Entities","spans":[{"start":18,"end":19,"text":"modes"}]}]}]},{"target":{"name":"Remainder","spans":[{"start":23,"end":24,"text":"remains"}]},"annotationSets":[{"rank":0,"score":22.84793521916924,"frameElements":[]}]},{"target":{"name":"Reasoning","spans":[{"start":26,"end":27,"text":"demonstrated"}]},"annotationSets":[{"rank":0,"score":44.540008018464746,"frameElements":[{"name":"Content","spans":[{"start":0,"end":23,"text":"Whether the RV144 immune correlates of risk will generalize to other populations vaccinated with similar immunogens with different modes and intensity of transmission"}]}]}]}],"tokens":["Whether","the","RV144","immune","correlates","of","risk","will","generalize","to","other","populations","vaccinated","with","similar","immunogens","with","different","modes","and","intensity","of","transmission","remains","to","be","demonstrated","."]}
{"frames":[{"target":{"name":"Trial","spans":[{"start":1,"end":2,"text":"trials"}]},"annotationSets":[{"rank":0,"score":44.95201791954416,"frameElements":[{"name":"Defendant","spans":[{"start":0,"end":1,"text":"Efficacy"}]}]}]},{"target":{"name":"Temporal_collocation","spans":[{"start":3,"end":4,"text":"now"}]},"annotationSets":[{"rank":0,"score":27.645036954261887,"frameElements":[]}]},{"target":{"name":"Purpose","spans":[{"start":4,"end":5,"text":"planned"}]},"annotationSets":[{"rank":0,"score":34.45956588366329,"frameElements":[{"name":"Time","spans":[{"start":3,"end":4,"text":"now"}]}]}]},{"target":{"name":"Aggregate","spans":[{"start":7,"end":8,"text":"populations"}]},"annotationSets":[{"rank":0,"score":32.59829517681791,"frameElements":[{"name":"Aggregate","spans":[{"start":7,"end":8,"text":"populations"}]}]}]},{"target":{"name":"Part_orientational","spans":[{"start":9,"end":10,"text":"southern"}]},"annotationSets":[{"rank":0,"score":11.538191945781515,"frameElements":[{"name":"Whole","spans":[{"start":10,"end":11,"text":"Africa"}]}]}]},{"target":{"name":"People","spans":[{"start":12,"end":13,"text":"men"}]},"annotationSets":[{"rank":0,"score":41.50741135998909,"frameElements":[{"name":"Person","spans":[{"start":12,"end":13,"text":"men"}]},{"name":"Descriptor","spans":[{"start":13,"end":20,"text":"who have sex with men in Thailand"}]}]}]},{"target":{"name":"Possession","spans":[{"start":14,"end":15,"text":"have"}]},"annotationSets":[{"rank":0,"score":35.134779426957984,"frameElements":[{"name":"Possession","spans":[{"start":15,"end":16,"text":"sex"}]},{"name":"Owner","spans":[{"start":12,"end":13,"text":"men"}]}]}]},{"target":{"name":"People","spans":[{"start":17,"end":18,"text":"men"}]},"annotationSets":[{"rank":0,"score":32.01871055441925,"frameElements":[{"name":"Person","spans":[{"start":17,"end":18,"text":"men"}]}]}]}],"tokens":["Efficacy","trials","are","now","planned","in","heterosexual","populations","in","southern","Africa","and","men","who","have","sex","with","men","in","Thailand","."]}
